GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkem Laboratories Ltd (NSE:ALKEM) » Definitions » Cyclically Adjusted Revenue per Share

Alkem Laboratories (NSE:ALKEM) Cyclically Adjusted Revenue per Share : ₹829.20 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Alkem Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Alkem Laboratories's adjusted revenue per share for the three months ended in Dec. 2023 was ₹277.995. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹829.20 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-24), Alkem Laboratories's current stock price is ₹5456.25. Alkem Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₹829.20. Alkem Laboratories's Cyclically Adjusted PS Ratio of today is 6.58.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alkem Laboratories was 6.56. The lowest was 4.33. And the median was 5.70.


Alkem Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Alkem Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkem Laboratories Cyclically Adjusted Revenue per Share Chart

Alkem Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alkem Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 797.58 813.65 829.20

Competitive Comparison of Alkem Laboratories's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkem Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's Cyclically Adjusted PS Ratio falls into.



Alkem Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alkem Laboratories's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=277.995/152.9243*152.9243
=277.995

Current CPI (Dec. 2023) = 152.9243.

Alkem Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201412 80.972 96.780 127.945
201503 78.998 97.163 124.335
201506 100.036 99.841 153.224
201509 113.881 101.753 171.151
201512 106.359 102.901 158.063
201603 96.066 102.518 143.300
201606 123.842 105.961 178.730
201609 136.996 105.961 197.714
201612 123.937 105.196 180.168
201703 104.671 105.196 152.161
201706 109.867 107.109 156.862
201709 155.485 109.021 218.099
201712 145.675 109.404 203.624
201803 126.554 109.786 176.280
201806 138.783 111.317 190.657
201809 160.467 115.142 213.122
201812 161.121 115.142 213.991
201903 147.333 118.202 190.612
201906 154.665 120.880 195.666
201909 189.376 123.175 235.114
201912 182.495 126.235 221.079
202003 158.600 124.705 194.489
202006 166.625 127.000 200.637
202009 197.610 130.118 232.246
202012 193.890 130.889 226.531
202103 171.936 131.771 199.538
202106 228.430 134.084 260.527
202109 234.181 135.847 263.620
202112 219.020 138.161 242.424
202203 197.508 138.822 217.572
202206 215.573 142.347 231.591
202209 257.546 144.661 272.257
202212 254.329 145.763 266.824
202303 229.436 146.865 238.903
202306 248.199 150.280 252.566
202309 287.733 151.492 290.453
202312 277.995 152.924 277.995

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Alkem Laboratories  (NSE:ALKEM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alkem Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5456.25/829.2
=6.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alkem Laboratories was 6.56. The lowest was 4.33. And the median was 5.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Alkem Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Alkem Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkem Laboratories (NSE:ALKEM) Business Description

Industry
Traded in Other Exchanges
Address
Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Alkem Laboratories (NSE:ALKEM) Headlines

No Headlines